Effectiveness of the XBB.1.5 COVID-19 Vaccines Against SARS-CoV-2 Hospitalisation Among Adults Aged ≥ 65 Years During the BA.2.86/JN.1 Predominant Period, VEBIS Hospital Study, Europe, November 2023 to May 2024

• Authors: ANTUNES Liliana; ROJAS-CASTRO Madelyn; LOZANO Marcos; MARTINEZ-BAZ Ivan; LEROUX-ROELS Isabel; BORG Maria-Louise; OROSZI Beatrix; FITZGERALD Margaret; DUERRWALD Ralf; JANCORIENE Ligita; MACHADO Ausenda; PETROVIC Goranka; LAZAR Mihaela; SOUČKOVÁ Lenka; BACCI Sabrina; HOWARD Jennifer; VERDASCA Nuno; BASILE Luca; CASTILLA Jesus; TERNEST Silke; DZIUGYTE Ausra; TURI Gergo; DUFFY Roisin; HACKMANN Carolin; KULIESE Monika; GOMEZ Veronica; MAKARIC Zvjezdana Lovric; MARIN Alexandru; HUSA Petr; NICOLAY Nathalie; ROSE Angela M C; TEAM VEBIS SARI VE network
• Year of publication: 2025
• Type: Article in Periodical
• Magazine / Source: Influenza and Other Respiratory Viruses
• MU Faculty or unit: Faculty of Medicine
• web: https://onlinelibrary.wiley.com/doi/10.1111/irv.70081
• Doi: http://dx.doi.org/10.1111/irv.70081
• Keywords: case-control study; elderly; severe acute respiratory infections (SARI); test-negative design; vaccine effectiveness
• Description: We estimated the effectiveness of the adapted monovalent XBB.1.5 COVID-19 vaccines against PCR-confirmed SARS-CoV-2 hospitalisation during the BA.2.86/JN.1 lineage-predominant period using a multicentre test-negative case-control study in Europe. We included older adults (>= 65 years) hospitalised with severe acute respiratory infection from November 2023 to May 2024. Vaccine effectiveness was 46% at 14-59 days and 34% at 60-119 days, with no effect thereafter. The XBB.1.5 COVID-19 vaccines conferred protection against BA.2.86 lineage hospitalisation in the first 4 months post-vaccination.